• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

神经拓展脊髓性肌萎缩症婴儿生物标志物研究中运动功能测试的可靠性。

Motor Function Test Reliability During the NeuroNEXT Spinal Muscular Atrophy Infant Biomarker Study.

机构信息

Department of Physical Therapy and Human Movement Sciences, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.

Department of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.

出版信息

J Neuromuscul Dis. 2018;5(4):509-521. doi: 10.3233/JND-180327.

DOI:10.3233/JND-180327
PMID:30223401
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8112280/
Abstract

BACKGROUND

The NeuroNEXT SMA Infant Biomarker Study, a two year, longitudinal, multi-center study of infants with SMA type 1 and healthy infants, presented a unique opportunity to assess multi-site rater reliability on three infant motor function tests (MFTs) commonly used to assess infants with SMA type 1.

OBJECTIVE

To determine the effect of prospective MFT rater training and the effect of rater experience on inter-rater and intra-rater reliability for the Test of Infant Motor Performance Screening Items (TIMPSI), the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP-INTEND) and the Alberta Infant Motor Scale (AIMS).

METHODS

Training was conducted utilizing a novel set of motor function test (MFT) videos to optimize accurate MFT administration and reliability for the study duration. Inter- and intra-rater reliability of scoring for the TIMPSI and inter-rater reliability of scoring for the CHOP INTEND and the AIMS was assessed using intraclass correlation coefficients (ICC). Effect of rater experience on reliability was examined using ICC. Agreement with 'expert' consensus scores was examined using Pearson's correlation coefficients.

RESULTS

Inter-rater reliability on all MFTs was good to excellent. Intra-rater reliability for the primary MFT, the TIMPSI, was excellent for the study duration. Agreement with 'expert' consensus was within predetermined limits (≥85%) after training. Evaluator experience with SMA and MFTs did not affect reliability.

CONCLUSIONS

Reliability of scores across evaluators was demonstrated for all three study MFTs and scores were reproducible on repeated administration. Evaluator experience had no effect on reliability.

摘要

背景

NeuroNEXT SMA 婴儿生物标志物研究是一项为期两年的纵向多中心研究,研究对象为 1 型 SMA 患儿和健康婴儿,为评估三种常用于评估 1 型 SMA 患儿的婴儿运动功能测试(MFT)的多站点评估者间可靠性提供了独特的机会。

目的

确定前瞻性 MFT 评估者培训的效果以及评估者经验对 Test of Infant Motor Performance Screening Items(TIMPSI)、费城儿童医院婴儿神经肌肉疾病测试(CHOP-INTEND)和 Alberta 婴儿运动量表(AIMS)的评估者间和评估者内可靠性的影响。

方法

使用一套新的运动功能测试(MFT)视频进行培训,以优化研究期间的 MFT 准确管理和可靠性。使用组内相关系数(ICC)评估 TIMPSI 的评估者间和评估者内评分以及 CHOP INTEND 和 AIMS 的评估者间评分的可靠性。使用 ICC 检查评估者经验对可靠性的影响。使用 Pearson 相关系数评估与“专家”共识评分的一致性。

结果

所有 MFT 的评估者间可靠性均为良好至优秀。TIMPSI 作为主要 MFT,在整个研究期间的评估者内可靠性均为优秀。培训后,与“专家”共识的一致性在预定范围内(≥85%)。评估者对 SMA 和 MFT 的经验并不影响可靠性。

结论

所有三种研究 MFT 的评估者间评分可靠性均得到证明,且在重复评估时评分具有可重复性。评估者经验对可靠性没有影响。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b60/8112280/089aeb9d7153/nihms-1696420-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b60/8112280/186b9a22c982/nihms-1696420-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b60/8112280/089aeb9d7153/nihms-1696420-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b60/8112280/186b9a22c982/nihms-1696420-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b60/8112280/089aeb9d7153/nihms-1696420-f0002.jpg

相似文献

1
Motor Function Test Reliability During the NeuroNEXT Spinal Muscular Atrophy Infant Biomarker Study.神经拓展脊髓性肌萎缩症婴儿生物标志物研究中运动功能测试的可靠性。
J Neuromuscul Dis. 2018;5(4):509-521. doi: 10.3233/JND-180327.
2
Evaluator Training and Reliability for SMA Global Nusinersen Trials1.脊髓性肌萎缩症全球依洛硫酸酯酶纳新酶临床试验 1 的评估者培训与可靠性
J Neuromuscul Dis. 2018;5(2):159-166. doi: 10.3233/JND-180301.
3
The Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND): test development and reliability.费城儿童医院婴儿神经肌肉疾病测试(CHOP INTEND):测试的开发和可靠性。
Neuromuscul Disord. 2010 Mar;20(3):155-61. doi: 10.1016/j.nmd.2009.11.014. Epub 2010 Jan 13.
4
Reliability and validity of the TIMPSI for infants with spinal muscular atrophy type I.用于I型脊髓性肌萎缩症婴儿的TIMPSI的可靠性和有效性。
Pediatr Phys Ther. 2013 Summer;25(2):140-8; discussion 149. doi: 10.1097/PEP.0b013e31828a205f.
5
Natural history of infantile-onset spinal muscular atrophy.婴儿型脊髓性肌萎缩症的自然病史。
Ann Neurol. 2017 Dec;82(6):883-891. doi: 10.1002/ana.25101. Epub 2017 Dec 8.
6
Revised Hammersmith Scale for spinal muscular atrophy: Inter and intra-rater reliability and agreement.修订后的脊髓性肌萎缩症 Hammersmith 量表:信度和一致性的评估。
PLoS One. 2022 Dec 21;17(12):e0278996. doi: 10.1371/journal.pone.0278996. eCollection 2022.
7
Baseline results of the NeuroNEXT spinal muscular atrophy infant biomarker study.NeuroNEXT 脊髓性肌萎缩症婴儿生物标志物研究的基线结果。
Ann Clin Transl Neurol. 2016 Jan 21;3(2):132-45. doi: 10.1002/acn3.283. eCollection 2016 Feb.
8
The test of infant motor performance: reliability in spinal muscular atrophy type I.婴儿运动能力测试:I型脊髓性肌萎缩症中的可靠性
Pediatr Phys Ther. 2008 Fall;20(3):242-6. doi: 10.1097/PEP.0b013e318181ae96.
9
Brazilian version of the CHOP INTEND scale: cross-cultural adaptation and validation.巴西版 CHOP INTEND 量表:跨文化调适与验证。
Arq Neuropsiquiatr. 2023 Sep;81(9):816-824. doi: 10.1055/s-0043-1772832. Epub 2023 Oct 4.
10
Inter- and Intra-rater Reliability of the Head Control Scale: Brief Report.头控制量表的组内和组间可靠性:简要报告。
Dev Neurorehabil. 2022 Jan;25(1):68-71. doi: 10.1080/17518423.2021.1970042. Epub 2021 Oct 31.

引用本文的文献

1
Advancing personalized spinal muscular atrophy care: matching the right biomarker to the right patient at the right time.推进个性化脊髓性肌萎缩症护理:在正确的时间为正确的患者匹配正确的生物标志物。
J Neurol. 2025 Sep 2;272(9):605. doi: 10.1007/s00415-025-13314-7.
2
Psychometric properties of clinician-reported and performance-based outcomes cited in a scoping review on spinal manipulation and mobilization for pediatric populations with diverse medical conditions: a systematic review.一项关于针对患有多种疾病的儿科人群进行脊柱推拿和松动术的范围综述中引用的临床医生报告结局和基于表现的结局的心理测量学特性:一项系统综述。
J Man Manip Ther. 2024 Jun;32(3):255-283. doi: 10.1080/10669817.2023.2269038. Epub 2023 Dec 9.
3

本文引用的文献

1
Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy.依库珠单抗治疗晚发性脊髓性肌萎缩症的疗效观察:一项随机、双盲、安慰剂对照 3 期试验
N Engl J Med. 2018 Feb 15;378(7):625-635. doi: 10.1056/NEJMoa1710504.
2
Diagnosis and management of spinal muscular atrophy: Part 1: Recommendations for diagnosis, rehabilitation, orthopedic and nutritional care.脊髓性肌萎缩症的诊断和管理:第 1 部分:诊断、康复、矫形和营养护理建议。
Neuromuscul Disord. 2018 Feb;28(2):103-115. doi: 10.1016/j.nmd.2017.11.005. Epub 2017 Nov 23.
3
Natural history of infantile-onset spinal muscular atrophy.
Consensus Guidelines for Improving Quality of Assessment and Training for Neuromuscular Diseases.
提高神经肌肉疾病评估与培训质量的共识指南
Front Genet. 2021 Nov 10;12:735936. doi: 10.3389/fgene.2021.735936. eCollection 2021.
4
Molecular Biomarkers for Spinal Muscular Atrophy: A Systematic Review.脊髓性肌萎缩症的分子生物标志物:一项系统综述。
Neurol Clin Pract. 2021 Aug;11(4):e524-e536. doi: 10.1212/CPJ.0000000000000872.
5
Update on Biomarkers in Spinal Muscular Atrophy.脊髓性肌萎缩症生物标志物的最新进展
Biomark Insights. 2021 Aug 14;16:11772719211035643. doi: 10.1177/11772719211035643. eCollection 2021.
6
Seven-Year Experience From the National Institute of Neurological Disorders and Stroke-Supported Network for Excellence in Neuroscience Clinical Trials.国家神经病学和中风学研究所支持的卓越神经科学临床试验网络的七年经验。
JAMA Neurol. 2020 Jun 1;77(6):755-763. doi: 10.1001/jamaneurol.2020.0367.
婴儿型脊髓性肌萎缩症的自然病史。
Ann Neurol. 2017 Dec;82(6):883-891. doi: 10.1002/ana.25101. Epub 2017 Dec 8.
4
Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy.依库珠单抗治疗婴儿型脊髓性肌萎缩症的疗效观察
N Engl J Med. 2017 Nov 2;377(18):1723-1732. doi: 10.1056/NEJMoa1702752.
5
Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy.脊髓性肌萎缩症的单剂量基因治疗。
N Engl J Med. 2017 Nov 2;377(18):1713-1722. doi: 10.1056/NEJMoa1706198.
6
Motor milestone assessment of infants with spinal muscular atrophy using the hammersmith infant neurological Exam-Part 2: Experience from a nusinersen clinical study.使用哈默史密斯婴儿神经学检查对脊髓性肌萎缩症婴儿进行运动里程碑评估 - 第2部分:来自诺西那生临床研究的经验。
Muscle Nerve. 2018 Jan;57(1):142-146. doi: 10.1002/mus.25705. Epub 2017 Jun 14.
7
218th ENMC International Workshop:: Revisiting the consensus on standards of care in SMA Naarden, The Netherlands, 19-21 February 2016.第218届ENMC国际研讨会:重新审视脊髓性肌萎缩症护理标准共识,荷兰纳尔登,2016年2月19日至21日。
Neuromuscul Disord. 2017 Jun;27(6):596-605. doi: 10.1016/j.nmd.2017.02.014. Epub 2017 Mar 2.
8
Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study.用nusinersen 治疗婴儿型脊肌萎缩症:一项 2 期、开放标签、剂量递增研究。
Lancet. 2016 Dec 17;388(10063):3017-3026. doi: 10.1016/S0140-6736(16)31408-8. Epub 2016 Dec 7.
9
Revised upper limb module for spinal muscular atrophy: Development of a new module.脊髓性肌萎缩症上肢模块修订版:新模块的开发
Muscle Nerve. 2017 Jun;55(6):869-874. doi: 10.1002/mus.25430. Epub 2017 Feb 6.
10
Baseline results of the NeuroNEXT spinal muscular atrophy infant biomarker study.NeuroNEXT 脊髓性肌萎缩症婴儿生物标志物研究的基线结果。
Ann Clin Transl Neurol. 2016 Jan 21;3(2):132-45. doi: 10.1002/acn3.283. eCollection 2016 Feb.